Unknown

Dataset Information

0

Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?

ABSTRACT: Immune checkpoint inhibitors (ICIs) have completely reshaped the treatment of many malignancies, with remarkable improvements in survival outcomes. In ovarian cancer (OC), however, this emerging class of drugs has not yet found a favorable use due to results from phase I and II studies, which have not suggested a substantial antitumoral activity of these agents when administered as monotherapy. Robust preclinical data seem to suggest that the combination ICIs with poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) may result in a synergistic activity; furthermore, data from phase II clinical studies, evaluating this combination, have shown encouraging outcomes especially for those OC patients not suitable for platinum retreatment. While waiting for ongoing phase III clinical trial results, which will clarify the role of ICIs in combination with PARPis in the newly diagnosed OC, this review aims to summarize the preclinical data and clinical evidence available to date.

SUBMITTER: Musacchio L 

PROVIDER: S-EPMC9294238 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?

Musacchio L L   Cicala C M CM   Camarda F F   Ghizzoni V V   Giudice E E   Carbone M V MV   Ricci C C   Perri M T MT   Tronconi F F   Gentile M M   Salutari V V   Scambia G G   Lorusso D D  

ESMO open 20220715 4

Immune checkpoint inhibitors (ICIs) have completely reshaped the treatment of many malignancies, with remarkable improvements in survival outcomes. In ovarian cancer (OC), however, this emerging class of drugs has not yet found a favorable use due to results from phase I and II studies, which have not suggested a substantial antitumoral activity of these agents when administered as monotherapy. Robust preclinical data seem to suggest that the combination ICIs with poly(ADP-ribose) polymerase (PA  ...[more]

Similar Datasets

Unknown Prospects for combining immune checkpoint blockade with PARP inhibition.
| S-EPMC6744711 | biostudies-literature
Unknown Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade.
| S-EPMC11424635 | biostudies-literature
Unknown Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade.
| S-EPMC8938703 | biostudies-literature
Unknown Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.
| S-EPMC7381609 | biostudies-literature
Unknown Perspective: cancer vaccines in the era of immune checkpoint blockade.
| S-EPMC6267701 | biostudies-literature
Unknown Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors.
| S-EPMC7352466 | biostudies-literature
Unknown CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.
| S-EPMC4984269 | biostudies-literature
Unknown Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade.
| S-EPMC8345045 | biostudies-literature
Unknown Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies.
| S-EPMC5053992 | biostudies-literature
Unknown Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?
| S-EPMC7872895 | biostudies-literature